ABPEP: Assessment of Biomarkers in Pregnancy on Unknown Location and Ectopic Pregnancy

Sponsor
Imperial College London (Other)
Overall Status
Recruiting
CT.gov ID
NCT04738370
Collaborator
Imperial College Healthcare NHS Trust (Other)
1,000
1
120.8
8.3

Study Details

Study Description

Brief Summary

To further develop the patient care pathway for women classified with a pregnancy of unknown location (PUL) and ectopic pregnancy (EP).

Condition or Disease Intervention/Treatment Phase
  • Other: Sample collection

Detailed Description

Purpose and design-There is a need for the patient care pathway to evolve in order to aid and improve the diagnosis and management of women with a pregnancy of unknown location (PUL) and ectopic pregnancy (EP). There is potential for this to be achieved by the incorporation of a statistical model that uses one or more novel markers identified by this study.

Recruitment-1000 patients. Inclusion: Patients attending the Early Pregnancy Unit (EPU) in the first trimester with a PUL or ectopic pregnancy on trans-vaginal ultrasound scan between the ages of 18-50 years. Exclusion: Patients diagnosed with cancer, presence of acute medical condition, patients aged less than 18 years, patients who cannot give fully informed study consent.

Consent - Posters will advertise the study. Patients in EPU will be invited to the study by a member of the clinical care team. Written consent will be required.

Confidentiality - The Chief Investigator will preserve the confidentiality of participants taking part in the study and is registered under the Data Protection Act. Patient consent forms will be stored securely within the study file. All patient identifiable information, where required, will be stored electronically on National Health Service (NHS) approved computers, accessible only by personnel involved in the study via password.

Conflict of interest - None involved in the study have a conflict of interest. Dissemination of results - No patient identifiable information will be included in the research report or publication. Anonymised results will be disseminated to scientific community by means of publication in peer-reviewed literature and presented at national and international meetings.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Assessment of Biomarkers in Pregnancy on Unknown Location and Ectopic Pregnancy
Actual Study Start Date :
Dec 8, 2014
Anticipated Primary Completion Date :
Dec 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Pregnancy of unknown location

Patients will be approached for recruitment following PUL classification. Sample collection at time of classification +/- 48 hours later, timed for when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.

Other: Sample collection
Bloods +/- urine +/- vaginal swabs taken

Ectopic Pregnancy

Patients will be approached for recruitment following Ectopic Pregnancy diagnosis. Ectopic pregnancies that are recruited as PUL do not need to be re-approached as they are already part of the study. Sample collection at time of diagnosis when bloods are taken as part of routine clinical practice +/- at any time patient attends for clinically indicated blood samples.

Other: Sample collection
Bloods +/- urine +/- vaginal swabs taken

Outcome Measures

Primary Outcome Measures

  1. PUL outcome prediction [7 years]

    The number of PUL patients correctly categorised as 'low risk' or 'high risk' based on the new logistical regression model

Secondary Outcome Measures

  1. Urinary BhCG and PUL [7 years]

    The number of PUL patients correctly categorised as 'low risk' or 'high risk' based on the interpretation of urine (rather than serum) BhCG

  2. Urine BhCG and Ectopic pregnancy [7 years]

    The number of ectopic pregnancies correctly risk stratified as being suitable for expectant or medical management based on the interpretation of urine (rather than serum) BhCG

  3. Plasma and Serum and PUL [7 years]

    Whether novel biomarkers present in serum and/or plasma and/or urine may have predictive value in determining 'low risk' versus 'high risk' PUL

  4. Plasma and Serum and Ectopic pregnancy [7 years]

    Whether novel biomarkers present in serum and/or plasma and/or urine may have predictive value in determining which women diagnosed with an ectopic pregnancy are suitable for expectant or medical management

  5. BhCG timing [7 years]

    Whether the timing of serial BhCG measurements has a significant impact on the risk stratification of PUL patients

  6. Novel biomarkers [7 years]

    Whether a novel candidate metabolite may have predictive value in determining 'low risk' versus 'high risk' PUL

  7. Other novel biomarkers [7 years]

    Whether a novel candidate metabolite may have predictive value in determining which women diagnosed with an ectopic pregnancy are suitable for expectant or medical management

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients attending the Early Pregnancy Unit in the first trimester of pregnancy (≤14 weeks gestation) aged between 18-50 years old and categorized as having a PUL or ectopic pregnancy
Exclusion Criteria:
  • Younger than 18 years of age

  • Women who in the opinion of the researcher by virtue of language or learning impairment would be unable to give fully informed consent to the study

  • Viable intrauterine pregnancy (the presence of a fetal pole with a fetal heartbeat within the uterine cavity)

  • Miscarriage

  • Presence of an acute medical condition

Contacts and Locations

Locations

Site City State Country Postal Code
1 Imperial College Healthcare NHS Trust London United Kingdom W12 0HS

Sponsors and Collaborators

  • Imperial College London
  • Imperial College Healthcare NHS Trust

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Imperial College London
ClinicalTrials.gov Identifier:
NCT04738370
Other Study ID Numbers:
  • 14HH2202
First Posted:
Feb 4, 2021
Last Update Posted:
Apr 1, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 1, 2022